Real-world Clinical Outcomes of Patients With Early-stage Lung Cancer After the Surgery

NCT06483698 · tracked via the Priya Life Science China tracker

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase

Observational

Started

2024-03-01

Last updated

2025-08-29

Condition(s) studied

Lung Cancer

Investigational drug(s) / intervention(s)

Sublobar resectionLobectomy

Sublobar resection: Sublobar resection is a series of surgical approaches for lung cancer.

Lobectomy: Lobectomy is the surgical approach for lung cancer.

Study summary

The goal of this observational study is to evaluate the efficacy and long-term clinical outcomes of early-stage lung cancer patients who have received surgery using the real-world data. The main questions it aims to answer are:

* What is the best surgical strategy for patients with early-stage lung cancer?
* What are the risk factors for early-stage lung cancer? Participants will receive surgery and the study will analyze the real-world data.

Eligibility

Sex

ALL

Min age

18 Years

Max age

85 Years

Healthy volunteers

Inclusion Criteria: 1. Aged between 18 and 85; 2. Did not receive neoadjuvant therapy before surgery; 3. No history of radiation therapy; 4. Eastern Cooperative Oncology Group (ECOG) score is 0-1; 5. Have complete clinically relevant information including imaging data; 6. All patients underwent relevant preoperative examinations; 7. Stage I lung cancer (International Association for the Study of Lung Cancer/The Union for International Cancer Control staging eighth edition); Exclusion Criteria: 1. Have previously received chemotherapy, radiotherapy and other anti-tumor therapy; 2. Data loss and error in medical records due to human/objective reasons.

Primary outcome measure(s)

Disease-free survival(DFS) — Defined as the time from the date of surgery until the date of first documented progression or death (by any cause in the absence of recurrence), whichever came first, assessed up to 10 years.
Defined as the time from the date of randomization until the date of disease recurrence or death (by any cause in the absence of recurrence).

Trial sites (1)

Facility	City	Region	Status
Shugeng Gao	Beijing	Beijing Municipality	Recruiting

More Cancer Institute and Hospital, Chinese Academy of Medical Sciences trials in China

Efficacy and Survival Analysis of Perioperative Treatment of Locally Advanced Gastric or Gastroesophageal Junction Cancer Active, not recruiting

A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC Enrolling by invitation

Predictive Value of Tumor Microenvironment PET/CT for Response and Prognosis in Aggressive Lymphoma: A Multicenter Study Recruiting

Multi-Reader Multi-Case Trial Evaluating Computer-Aided Tool for Prognostic Prediction of Colorectal Liver Metastases Recruiting

Real-World RAIRI-Guided Risk Stratification for Adjuvant Therapy Benefit After Chemoradiotherapy in NPC Recruiting

Other trials for the same condition

Research on Early Screening and Diagnosis of Pulmonary Nodules Based on Novel Non-invasive Technologies. Recruiting

Study on the Diagnosis of Ground-glass Lung Cancer by Microwave Ablation Combined With Puncture Biopsy Recruiting

Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer Recruiting

Application of DCE-MRI Based on 4D FreeBreathing in Predicting the Efficacy of Immune and Targeted Therapy in Lung Cancer Recruiting

Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06483698 on ClinicalTrials.gov ↗ ← All trials in China